Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis

Infection and Immunity

Volumn 71, Issue 1, 2003, Pages 401-410

  Ahmed, Saeed ^a   Colmenares, M ^a   Soong, L ^a   Goldsmith Pestana, K ^a   Munstermann, L ^a   Molina, R ^b   McMahon Pratt, Diane ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; LEISHMANIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; LEISHMANIA INFANTUM; LYMPH NODE; MOUSE; NONHUMAN; PATHOGENESIS; PERSISTENT INFECTION; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; TH1 CELL; TH2 CELL; VISCERAL LEISHMANIASIS;

ADMINISTRATION, CUTANEOUS; ANIMALS; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS, INTRAVENOUS; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; LYMPHOID TISSUE; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES; SKIN; VIRULENCE;

EID: 0037218228     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.71.1.401-410.2003     Document Type: Article

References (78)

1. Afrin, F., and N. Ali. 1997. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect. Immun. 65:2371-2377.
2. Alexander, J., K. C. Carter, N. Al-Fasi, A. Satoskar, and F. Brombacher. 2000. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur. J. Immunol. 30:2935-2943.
3. Alvar, J., B. Gutierrez-Solar, R. Molina, R. Lopez-Velez, A. Garcia-Camacho, P. Martinez, F. Laguna, E. Cercenado, and A. Galmes. 1992. Prevalence of Leishmania infection among AIDS patients. Lancet 339:1427.
4. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245-252.
5. Belkaid, Y., K. F. Hoffmann, S. Mendez, S. Kamhawi, M. C. Udey, T. A. Wynn, and D. L. Sacks. 2001. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194: 1497-1506.
6. Belkaid, Y., S. Kamhawi, G. Modi, J. Valenzuela, N. Noben-Trauth, E. Rowton, J. Ribeiro, and D. L. Sacks. 1998. Development of a natural model of cutaneous leishmaniasis: Powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J. Exp. Med. 188:1941-1953.
7. Belkaid, Y., S. Mendez, R. Lira, N. Kadambi, G. Milon, and D. Sacks. 2000. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J. Immunol. 165:969-977.
8. Bhattacharyya, S., S. Ghosh, P. L. Jhonson, S. K. Bhattacharya, and S. Majumdar. 2001. Immunomodulatory role of interleukin-10 in visceral leishmaniasis: Defective activation of protein kinase C-mediated signal transduction events. Infect. Immun. 69:1499-1507.
9. Boelaert, M., B. Criel, J. Leeuwenburg, W. Van Damme, D. Le Ray, and P. Van der Stuyft. 2000. Visceral leishmaniasis control: A public health perspective. Trans. R. Soc. Trop. Med. Hyg. 94:465-471.
10. Champsi, J., and D. McMahon-Pratt. 1988. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect. Immun. 56:3272-3279.
11. Ding, L., P. S. Linsley, L. Y. Huang, R. N. Germain, and E. M. Shevach. 1993. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J. Immunol. 151:1224-1234.
12. Duboise, S. M. 1994. Developmentally Regulated Antigens of Leishmania Pifanoi Amastigotes: Characterization, Patterns of Expression, and Immunoprophylactic Potential, p. 1-238. Ph.D. thesis. Yale University, New Haven, Conn.
13. Engwerda, C. R., M. L. Murphy, S. E. Cotterell, S. C. Smelt, and P. M. Kaye. 1998. Neutralization of IL-12 demonstrates the existence of discrete organspecific phases in the control of Leishmania donovani. Eur. J. Immunol. 28:669-680.
14. Gasim, S., A. M. Elhassan, E. A. Khalil, A. Ismail, A. M. Kadaru, A. Kharazmi, and T. G. Theander. 1998. High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. Clin. Exp. Immunol. 111:64-69.
15. Ghalib, H. W., M. R. Piuvezam, Y. A. Skeiky, M. Siddig, F. A. Hashim, A. M. el-Hassan, D. M. Russo, and S. G. Reed. 1993. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J. Clin. Investig. 92:324-329.
16. Ghosh, A., S. Labrecque, and G. Matlashewski. 2001. Protection against Leishmania donovani infection by DNA vaccination: Increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine 19: 3169-3178.
17. Gomes, N. A., V. Barreto-de-Souza, M. E. Wilson, and G. A. DosReis. 1998. Unresponsive CD4+ T lymphocytes from Leishmania chagasi-infected mice increase cytokine production and mediate parasite killing after blockade of B7-1/CTLA-4 molecular pathway. J. Infect. Dis. 178:1847-1851.
18. Gomes, N. A., C. R. Gattass, V. Barreto-De-Souza, M. E. Wilson, and G. A. DosReis. 2000. TGF-beta mediates CTLA-4 suppression of cellular immunity in murine kalaazar. J. Immunol. 164:2001-2008.
19. Gong, J. H., M. Zhang, R. L. Modlin, P. S. Linsley, D. Iyer, Y. Lin, and P. F. Barnes. 1996. Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA-4 expression. Infect. Immun. 64:913-918.
20. Gorak, P. M., C. R. Engwerda, and P. M. Kaye. 1998. Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection. Eur. J. Immunol. 28:687-695.
21. Groux, H., F. Cottrez, M. Rouleau, S. Mauze, S. Antonenko, S. Hurst, T. McNeil, M. Bigler, M. G. Roncarolo, and R. L. Coffman. 1999. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigenpresenting cells. J. Immunol. 162:1723-1729.
22. Gurunathan, S., D. L. Sacks, D. R. Brown, S. L. Reiner, H. Charest, N. Glaichenhaus, and R. A. Seder. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J. Exp. Med. 186:1137-1147.
23. Hall, L. R., and R. G. Titus. 1995. Sand fly vector saliva selectively modulates macrophage functions that inhibit killing of Leishmania major and nitric oxide production. J. Immunol. 155:3501-3506.
24. Howard, M. K., G. Sayers, and M. A. Miles. 1987. Leishmania donovani metacyclic promastigotes: Transformation in vitro, lectin agglutination, complement resistance, and infectivity. Exp. Parasitol. 64:147-156.
25. Jardim, A., J. Alexander, H. S. Teh, D. Ou, and R. W. Olafson. 1990. Immunoprotective Leishmania major synthetic T cell epitopes. J. Exp. Med. 172:645-648.
26. Kane, M. M., and D. M. Mosser. 2001. The role of IL-10 in promoting disease progression in leishmaniasis. J. Immunol. 166:1141-1147.
27. Karp, C. L., S. H. el-Safi, T. A. Wynn, M. M. Satti, A. M. Kordofani, F. A. Hashim, M. Hag-Ali, F. A. Neva, T. B. Nutman, and D. L. Sacks. 1993. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J. Clin. Investig. 91:1644-1648.
28. Kaye, P. M., A. J. Curry, and J. M. Blackwell. 1991. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis. J. Immunol. 146:2763-2770.
29. Kenney, R. T., D. L. Sacks, A. A. Gam, H. W. Murray, and S. Sundar. 1998. Splenic cytokine responses in Indian kala-azar before and after treatment. J. Infect. Dis. 177:815-818.
30. Killick-Kendrick, R., M. Killick-Kendrick, E. Pinelli, G. Del Real, R. Molina, M. M. Vitutia, M. C. Canavate, and J. Nieto. 1994. A laboratory model of canine leishmaniasis: The inoculation of dogs with Leishmania infantum promastigotes from midguts of experimentally infected phlebotomine sandflies. Parasite 1:311-318.
31. Laufs, H., K. Muller, J. Fleischer, N. Reiling, N. Jahnke, J. C. Jensenius, W. Solbach, and T. Laskay. 2002. Intracellular survival of Leishmania major in neutrophil granulocytes after uptake in the absence of heat-labile serum factors. Infect. Immun. 70:826-835.
32. Laurenti, M. D., C. E. Corbett, M. N. Sotto, I. L. Sinhorini, and H. Goto. 1996. The role of complement in the acute inflammatory process in the skin and in host-parasite interaction in hamsters inoculated with Leishmania (Leishmania)chagasi. Int. J. Exp. Pathol. 77:15-24.
33. Leclercq, V., M. Lebastard, Y. Belkaid, J. Louis, and G. Milon. 1996. The outcome of the parasitic process initiated by Leishmania infantum in laboratory mice: A tissue-dependent pattern controlled by the Lsh and MHC loci. J. Immunol. 157:4537-4545.
34. Lehmann, J., K. H. Enssle, I. Lehmann, A. Emmendorfer, and M. L. Lohmann-Matthes. 2000. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J. Interferon Cytokine Res. 20:63-77.
35. Magill, A. J. 1995. Epidemiology of the leishmaniases. Dermatol. Clin. 13: 505-523.
36. Mbow, M. L., J. A. Bleyenberg, L. R. Hall, and R. G. Titus. 1998. Phlebotomus papatasi sand fly salivary gland lysate down-regulates a Th1, but upregulates a Th2, response in mice infected with Leishmania major. J. Immunol. 161:5571-5577.
37. McSorley, S. J., D. Xu, and F. Y. Liew. 1997. Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters. Infect. Immun. 65:171-178.
38. Melby, P. C., F. Andrade-Narvaez, B. J. Darnell, and G. Valencia-Pacheco. 1996. In situ expression of interleukin-10 and interleukin-12 in active human cutaneous leishmaniasis. FEMS Immunol. Med. Microbiol. 15:101-107.
39. Melby, P. C., G. B. Ogden, H. A. Flores, W. Zhao, C. Geldmacher, N. M. Biediger, S. K. Ahuja, J. Uranga, and M. Melendez. 2000. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect. Immun. 68: 5595-5602.
40. Melby, P. C., J. Yang, W. Zhao, L. E. Perez, and J. Cheng. 2001. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun. 69:4719-4725.
41. Melby, P. C., Y. Z. Yang, J. Cheng, and W. Zhao. 1998. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect. Immun. 66:18-27.
42. Miralles, G. D., M. Y. Stoeckle, D. F. McDermott, F. D. Finkelman, and H. W. Murray. 1994. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect. Immun. 62:1058-1063.
43. Molina, R. 1993. Laboratory adaptation of an autochthonous colony of Phlebotmus perniciosus Newstead, 1911 (Diptera: Psychodidae). Res. Rev. Parasitol. 51:87-89.
44. Moore, K. W., A. O'Garra, R. de Waal Malefyt, P. Vieira, and T. R. Mosmann. 1993. Interleukin-10. Annu. Rev. Immunol. 11:165-190.
45. Morris, R. V., C. B. Shoemaker, J. R. David, G. C. Lanzaro, and R. G. Titus. 2001. Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J. Immunol. 167: 5226-5230.
46. Mukhopadhyay, J., E. F. Rangel, K. Ghosh, and L. E. Munstermann. 1997. Patterns of genetic variability in colonized strains of Lutzomyia longipalpis (Diptera: Psychodidae) and its consequences. Am. J. Trop. Med. Hyg. 57: 216-221.
47. Murphy, M. L., S. E. Cotterell, P. M. Gorak, C. R. Engwerda, and P. M. Kaye. 1998. Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. J. Immunol. 161:4153-4160.
48. Murphy, M. L., U. Wille, E. N. Villegas, C. A. Hunter, and J. P. Farrell. 2001. IL-10 mediates susceptibility to Leishmania donovani infection. Eur. J. Immunol. 31:2848-2856.
49. Murray, H. W., J. Hariprashad, and R. L. Coffman. 1997. Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. J. Exp. Med. 185:867-874.
50. Murray, H. W., A. Jungbluth, E. Ritter, C. Montelibano, and M. W. Marino. 2000. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect. Immun. 68:6289-6293.
51. Murray, H. W., G. D. Miralles, M. Y. Stoeckle, and D. F. McDermott. 1993. Role and effect of IL-2 in experimental visceral leishmaniasis. J. Immunol. 151:929-938.
52. Nuwayri-Salti, N., M. Matta, Z. Shbaklo, M. Lakkis, and Z. E. Kabbani. 1998. Behavior in a mouse model of isolates of Leishmania donovani sensu lato cultured from the blood of patients with chronic cutaneous lesions. Am. J. Trop. Med. Hyg. 58:710-714.
53. Pan, A. A., and D. McMahon-Pratt. 1988. Monoclonal antibodies specific for the amastigote stage of Leishmania pifanoi. I. Characterization of antigens associated with stage- and species-specific determinants. J. Immunol. 140: 2406-2414.
54. Paraguai de Souza, E., R. R. Bernardo, M. Palatnik, and C. B. Palatnik de Sousa. 2001. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani. Vaccine 19:3104-3115.
55. Pearson, R. D., and R. T. Steigbigel. 1981. Phagocytosis and killing of the protozoan Leishmania donovani by human polymorphonuclear leukocytes. J. Immunol. 127:1438-1443.
56. Rachamim, N., and C. L. Jaffe. 1993. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis. J. Immunol. 150:2322-2331.
57. Shibata, Y., L. A. Foster, M. Kurimoto, H. Okamura, R. M. Nakamura, K. Kawajiri, J. P. Justice, M. R. Van Scott, Q. N. Myrvik, and W. J. Metzger. 1998. Immunoregulatory roles of IL-10 in innate immunity: IL-10 inhibits macrophage production of IFN-gamma-inducing factors but enhances NK cell production of IFN-gamma. J. Immunol. 161:4283-4288.
58. Soong, L., C. H. Chang, J. Sun, B. J. Longley, Jr., N. H. Ruddle, R. A. Flavell, and D. McMahon-Pratt. 1997. Role of CD4+ T cells in pathogenesis associated with Leishmania amazonensis infection. J. Immunol. 158:5374-5383.
59. Soong, L., S. M. Duboise, P. Kima, and D. McMahon-Pratt. 1995. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect. Immun. 63:3559-3566.
60. Stager, S., D. F. Smith, and P. M. Kaye. 2000. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J. Immunol. 165:7064-7071.
61. Streit, J. A., T. J. Recker, F. G. Filho, S. M. Beverley, and M. E. Wilson. 2001. Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms. J. Immunol. 166:1921-1929.
62. Sulahian, A., Y. J. Garin, F. Pratlong, J. P. Dedet, and F. Derouin. 1997. Experimental pathogenicity of viscerotropic and dermotropic isolates of Leishmania infantum from immunocompromised and immunocompetent patients in a murine model. FEMS Immunol. Med. Microbiol. 17:131-138.
63. Tacchini-Cottier, F., C. Zweifel, Y. Belkaid, C. Mukankundiye, M. Vasei, P. Launois, G. Milon, and J. A. Louis. 2000. An immunomodulatory function for neutrophils during the induction of a CD4+ Th2 response in BALB/c mice infected with Leishmania major. J. Immunol. 165:2628-2636.
64. Taylor, A. P., and H. W. Murray. 1997. Intracellular antimicrobial activity in the absence of interferon-gamma: Effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice. J. Exp. Med. 185:1231-1239.
65. Theodos, C. M., and R. G. Titus. 1993. Salivary gland material from the sand fly Lutzomyia longipalpis has an inhibitory effect on macrophage function in vitro. Parasite Immunol. 15:481-487.
66. Titus, R. G., M. Marchand, T. Boon, and J. A. Louis. 1985. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 7:545-555.
67. Titus, R. G., and J. M. Ribeiro. 1988. Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity. Science 239:1306-1308.
68. Tumang, M. C., C. Keogh, L. L. Moldawer, D. C. Helfgott, R. Teitelbaum, J. Hariprashad, and H. W. Murray. 1994. Role and effect of TNF-alpha in experimental visceral leishmaniasis. J. Immunol. 153:768-775.
69. Ulczak, O. M., and J. M. Blackwell. 1983. Immunoregulation of genetically controlled acquired responses to Leishmania donovani infection in mice: The effects of parasite dose, cyclophosphamide and sublethal irradiation. Parasite Immunol. 5:449-463.
70. Ulczak, O. M., E. Ghadirian, E. Skamene, J. M. Blackwell, and P. A. Kongshavn. 1989. Characterization of protective T cells in the acquired response to Leishmania donovani in genetically determined cure (H-2b) and noncure (H-2d) mouse strains. Infect. Immun. 57:2892-2899.
71. Warburg, A., E. Saraiva, G. C. Lanzaro, R. G. Titus, and F. Neva. 1994. Saliva of Lutzomyia longipalpis sibling species differs in its composition and capacity to enhance leishmaniasis. Phil. Trans. R. Soc. Lond. Ser. B 345: 223-230.
72. White, A. C., Jr., and D. McMahon-Pratt. 1990. Prophylactic immunization against experimental Leishmania donovani infection by use of a purified protein vaccine. J. Infect. Dis. 161:1313-1314.
73. White, A. C., Jr., and D. McMahon-Pratt. 1988. Purification and characterization of an 80-kilodalton membrane protein from Leishmania donovani. Infect. Immun. 56:2385-2391.
74. Wilson, M. E., D. J. Innes, A. D. Sousa, and R. D. Pearson. 1987. Early histopathology of experimental infection with Leishmania donovani in hamsters. J. Parasitol. 73:55-63.
75. Wilson, M. E., M. Sandor, A. M. Blum, B. M. Young, A. Metwali, D. Elliott, R. G. Lynch, and J. V. Weinstock. 1996. Local suppression of IFN-gamma in hepatic granulomas correlates with tissue-specific replication of Leishmania chagasi. J. Immunol. 156:2231-2239.
76. Wilson, M. E., B. M. Young, B. L. Davidson, K. A. Mente, and S. E. McGowan. 1998. The importance of TGF-beta in murine visceral leishmaniasis. J. Immunol. 161:6148-6155.
77. World Health Organization. 2000. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases: Leishmaniasis and Leishmania/HIV Coinfection, vol. 2000. WHO/CDS/CSR/ISR/2000.1. [Online.] http://www.who.int/emc-documents/surveillance/docs.
78. Yin, H., D. E. Norris, and G. C. Lanzaro. 2000. Sibling species in the Lutzomyia longipalpis complex differ in levels of mRNA expression for the salivary peptide, maxadilan. Insect Mol. Biol. 9:309-314.